Abstract Details

Title Detailed Analysis of Current Migraine Treatment Trends by Treatment Groups in a Large Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases

Topic Headache

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 12-003

Objective We evaluated a large subset of the US Migraine population under various groups stratified by medication to analyze current migraine treatment trends.

Background With the emergence of calcitonin gene-related peptide (anti-CGRP) medications the migraine treatment landscape has evolved recently and a detailed review of a large subset of the US Migraine population may offer insight into current prescription trends.

Design/Methods Based on ICD-10 codes (Health Verity claims data; 8/2018-7/2021; N=187,780) Chronic vs. Other migraine groups were defined under the following: anti-CGRP, non-specific migraine preventive treatment, migraine-specific acute treatment, non-specific acute treatment, and no treatment. Baseline and Follow-up periods defined as 12 months prior and after the index.

Results

At baseline, Chronic Migraine group (N=21,879) were further subdivided into: non-specific migraine preventive treatment (41.2%), no treatment (17.6%), anti-CGRP (16.1%), migraine-specific acute (15.0%), and non-specific acute treatment (10.0%) groups. Other Migraine group (N=165,901) were divided under following subgroups: non-specific migraine preventive treatment group (34.4%), no treatment (26.9%), migraine-specific acute (18.9%), non-specific acute treatment (15.4%), and anti-CGRP (4.4%) groups.

The anti-CGRP treatment group had the highest percentage of all-cause Neurology visits among the 5 treatment groups in Chronic and Other Migraine types during Baseline and Follow-up periods. Acute Non-Specific treatment groups had the most frequent visits to the emergency department in both migraine types during Baseline and Follow-up.

Conclusions Prescription trends from a large subset of the US Migraine population revealed significant differences among treatment groups. The recent introduction of novel calcitonin gene-related peptide (anti-CGRP) medications has transformed the migraine treatment landscape.

Authors/Disclosures
Alexander Kuka (Click Therapeutics) PRESENTER	Dr. Kuka has received personal compensation for serving as an employee of Click Therapeutics, Inc..
Olya Besedina (Click Therapeutics Inc.)	Miss Besedina has nothing to disclose.
Mariya Petrova (Click Therapeutics)	Mariya Petrova has received personal compensation for serving as an employee of Click Therapeutics. Mariya Petrova has received research support from NIH.
Brendan Hare	No disclosure on file
Alankar Gupta, MD (Click Therapeutics)	Dr. Gupta has nothing to disclose.
Shaheen E. Lakhan, MD, PhD, MEd, FAAN	Dr. Lakhan has received personal compensation for serving as an employee of Zogenix, Fern Health, Thriveworks, The Learning Corp, TriNet, Click Therapeutics. Dr. Lakhan has received personal compensation in the range of $1,000,000+ for serving as a Consultant for Shaheen Lakhan, MD, PhD, LLC. Dr. Lakhan has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine, Fern Health, Lin Health. Dr. Lakhan has received personal compensation in the range of $500,000-$999,999 for serving as an officer or member of the Board of Directors for Click Therapeutics, SpineThera. Dr. Lakhan has stock in Zogenix, NeuroSport, Click Therapeutics, SpineThera.

��ɫ��

��ɫ��